Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $4.15 million. The enterprise value is -$3.78 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 4.48 million shares outstanding. The number of shares has increased by 4.24% in one year.
| Current Share Class | 4.48M |
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | +4.24% |
| Shares Change (QoQ) | +40.92% |
| Owned by Insiders (%) | 4.13% |
| Owned by Institutions (%) | 2.83% |
| Float | 4.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.03 |
| Forward PS | n/a |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.91
| Current Ratio | 7.91 |
| Quick Ratio | 7.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -797.97 |
Financial Efficiency
Return on equity (ROE) is -52.02% and return on invested capital (ROIC) is -35.51%.
| Return on Equity (ROE) | -52.02% |
| Return on Assets (ROA) | -28.88% |
| Return on Capital (ROIC) | -35.51% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.26M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.22% in the last 52 weeks. The beta is 1.36, so Silo Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -43.22% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 35.57 |
| Average Volume (20 Days) | 201,263 |
Short Selling Information
The latest short interest is 67,438, so 1.50% of the outstanding shares have been sold short.
| Short Interest | 67,438 |
| Short Previous Month | 134,766 |
| Short % of Shares Out | 1.50% |
| Short % of Float | 1.66% |
| Short Ratio (days to cover) | 0.98 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$3.78 million in losses. Loss per share was -$1.15.
| Revenue | 72,102 |
| Gross Profit | 66,264 |
| Operating Income | -4.06M |
| Pretax Income | -3.60M |
| Net Income | -3.78M |
| EBITDA | n/a |
| EBIT | -4.06M |
| Loss Per Share | -$1.15 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 8.02M |
| Total Debt | n/a |
| Net Cash | 8.02M |
| Net Cash Per Share | $1.79 |
| Equity (Book Value) | 6.78M |
| Book Value Per Share | 1.51 |
| Working Capital | 7.22M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.83M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.83M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
| Gross Margin | 91.90% |
| Operating Margin | -5,625.46% |
| Pretax Margin | -5,150.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -4,673.92% |